Evidence map›Paper›PMID 41571299›Full record

Trial reportJournal for immunotherapy of cancer2026

Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer.

Dung T Le, Gunnar Folprecht, Anna M Varghese, Martin Gutierrez, Marcus Noel, Nikolaos A Trikalinos, Eric Chen, Farshid Dayyani, S Lindsey Davis, Wen Wee Ma and 10 more

Registry-linked trialAbstract readClinical Trial, Phase IClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03184870 (A Phase 1b/2 Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03184870 phase1 / phase2completednot on this map

A Phase 1b/2 Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors

TypeinterventionalSponsorBristol-Myers SquibbRan2017 to 2023Enrolled332ConditionsColorectal Cancer, Pancreatic CancerArmsBMS-813160, Nivolumab, Nab-paclitaxel, Gemcitabine, 5-fluorouracil (5-FU)
3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Review
  3. [Novel therapeutic strategies for liver metastases driven by the common microenvironment].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Dung T LeSidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, Maryland, USA dle@jhmi.edu.
Gunnar FolprechtMedical Department I, TU Dresden/Universitaetsklinikum Carl Gustav Carus, Dresden, Germany.
Anna M VargheseMemorial Sloan Kettering Nassau, Uniondale, New York, USA.
Martin GutierrezHackensack University Medical Center Center, Hackensack, New Jersey, USA.
Marcus NoelLombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC, USA.
Nikolaos A TrikalinosWashington University School of Medicine in Saint Louis, St Louis, Missouri, USA.
Eric ChenPrincess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.ORCID http://orcid.org/0000-0002-4581-8848
Farshid DayyaniUC Irvine Medical Center, Orange, Florida, USA.
S Lindsey DavisUniversity of Colorado Cancer Center, Denver, Colorado, USA.
Wen Wee MaMayo Clinic in Minnesota, Rochester, Minnesota, USA.
Atrayee BasuMallickThomas Jefferson University, Philadelphia, Pennsylvania, USA.
Ignacio Garrido-LagunaHuntsman Cancer Institute, Salt Lake City, Utah, USA.
Mayu OsawaBristol Myers Squibb Co, Princeton, New Jersey, USA.ORCID http://orcid.org/0000-0001-5215-9994
Shaun O'BrienBristol Myers Squibb Co, Princeton, New Jersey, USA.
Ruslan D NovosiadlyBristol Myers Squibb Co, Princeton, New Jersey, USA.
Ke XuBristol Myers Squibb Co, Princeton, New Jersey, USA.
Danielle M GreenawaltBristol Myers Squibb, Lawrenceville, New Jersey, USA.
Santanu DuttaBiostatistics, Bristol Myers Squibb, Princeton, New Jersey, USA.
Christina Twyman Saint VictorBristol Myers Squibb Co, Princeton, New Jersey, USA.
Heinz-Josef LenzUSC Norris Comprehensive Cancer Center, Los Angeles, California, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Elisa de Stanchina · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundCysteine-cysteine chemokine receptors 2 (CCR2) and 5 (CCR5) contribute to immune suppression in tumor microenvironments. CCR2 and CCR5 antagonists have demonstrated antitumor activity in pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC), respectively. This phase 1b/2, open-label study evaluated BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy±nivolumab in advanced PDAC or metastatic CRC.

methodsPart 1 included patients with metastatic untreated (first-line (1L)) PDAC, 1L CRC, or previously treated (second or third line (2/3L)) microsatellite stable (MSS) CRC. Patients received 2 weeks of BMS-813160 monotherapy (300 mg two times a day, 600 mg once daily, 300 mg once daily, or 150 mg once daily) and then BMS-813160+chemotherapy (gemcitabine+nab-paclitaxel (gem/nabP; 1L PDAC), 5-fluorouracil+leucovorin+irinotecan (FOLFIRI; 1L CRC)), or nivolumab (2/3L MSS CRC).Part 2 included patients with metastatic 1L PDAC or 2L CRC. Patients received BMS-813160 300 mg two times a day+gem/nabP±nivolumab (1L PDAC), BMS-813160 300 mg two times a day or 150 mg once daily+FOLFIRI (2L CRC), or chemotherapy alone. Primary endpoints were safety and pharmacodynamics (Part 1) and efficacy (Part 2).

resultsIn Part 1, 22 of 75 (29%) and 54 of 72 (72%) patients experienced a treatment-related adverse event during monotherapy lead-in and overall, respectively. Two dose-limiting toxicities (rash and pericardial effusion with pericarditis, both grade 3) occurred. In Part 2, patients with 1L PDAC who received BMS-813160 300 mg two times a day+gem/nabP+nivolumab achieved an overall response rate (ORR) of 37% (13/35); the median duration of response (DOR) was 45 weeks (95% CI 26.1 to not evaluable). ORRs with BMS-813160 300 mg two times a day+gem/nabP and gem/nabP alone were 26% (9/35) and 28% (9/32), respectively; median DORs were 121 and 31 weeks, respectively. Progression-free survival rates at 24 weeks were 56% (BMS-813160 300 mg two times a day+gem/nabP+nivolumab), 56% (BMS-813160 300 mg two times a day+gem/nabP), and 50% (gem/nabP). ORRs in 2L CRC were 19% (6/32; BMS-813160 300 mg two times a day+FOLFIRI), 13% (4/32; BMS-813160 150 mg once daily+FOLFIRI), and 27% (7/26; FOLFIRI).

conclusionsIn 1L PDAC, BMS-813160 300 two times a day+gem/nabP±nivolumab demonstrated durable antitumor response and was well tolerated. BMS-813160 combination regimens were tolerable in other cohorts, but clinical efficacy was not demonstrated. TRIAL REGISTRATION NUMBER: NCT03184870.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsNivolumabPancreatic NeoplasmsReceptors, CCR2Receptors, CCR5AdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedCCR2 protein, humanCCR5 protein, humanNivolumabReceptors, CCR2Receptors, CCR5AdenocarcinomaColorectal CancerCombination therapyTumor microenvironment - TME

Identifiers

PMID41571299
PMCPMC12829384

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.